Covid-19: Healthcare daily update – cardiac injury can occur in those with no previous risk – BCG vaccination may offer heterologous immunity

24 April 2020 (Last Updated April 24th, 2020 12:56)

24 April

Treatment of cardiovascular disease during the Covid-19 pandemic
New research has shown that although those with CVD are at risk, cardiac injury can occur in those with confirmed Covid-19 and no previous cardiovascular (CV) risk. This will increase the use of and the demand for various CV treatments as patients are treated symptomatically and potentially longer-term if the myocardium effects are long-lasting.

BCG vaccination may induce heterologous immunity and protect against Covid-19
Preliminary reports from epidemiological studies suggest that countries with universal BCG vaccination programs have been impacted less by Covid-19, leading researchers to theorise that BCG vaccination may offer some level of heterologous immunity against Covid-19.

The impact of big pharma on Covid-19
Pharmaceutical companies taking centre stage in the Covid-19 fight, such as Gilead and Eli Lilly, are seeing positive growth on the stock market and a new burst of innovation in the infectious disease landscape as the race for treatment approval for a Covid-19 therapy takes off. But what impact are pharmaceutical companies having in a time of strong clinical need?